Henlius Acquires Two Novel Immunotherapy Candidates in $196.5 Million Deal
publication date: Jun 28, 2022
Shanghai Henlius Biotech acquired Greater China rights to two early-stage bifunctional sialidase candidates from Palleon Pharma, a Waltham, MA biopharma, in a deal with $196.5 million in development and sales milestones. Palleon develops glycol-immunology products for cancer and inflammatory diseases. Henlius will have rights to develop Palleon’s bifunctional HER2-Sialidase, currently in preclinical development, and a second bifunctional sialidase to be developed and aimed at a proprietary Henlius target. Henlius develops affordable and innovative biologic for indications in oncology, autoimmune and ophthalmic diseases. More details.....
Stock Symbol: (HK: 2696)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.